$3.53
+0.14 (+4.13%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BCTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 with posted results
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 6.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: SV-BR-1-GM · Drug: Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice | Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer | 404 | Dec 2027 | ≤ 499 d | 2026-08-17 |
| A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerNCT06471673Safety as assessed by adverse events (AEs), including serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort | Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast | 18 | 2025-04-30 | — | 2024-08-26 |
| Combination Study of SV-BR-1-GM With RetifanlimabNCT03328026Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]Randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: SV-BR-1-GM · Drug: Low dose cyclophosphamide, Interferon Inoculation, retifanlimab | Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic | 36 | 2026-03-24actual | — | 2026-03-27 |
| SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerNCT03066947results2021-01-29Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety]Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: SV-BR-1-GM, Interferon-alpha-2b · Drug: Cyclophosphamide | Breastcancer, Breast Neoplasm | 24 | 2018-11-22actual | — | 2021-01-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19